Intellia Therapeutics, Inc. (NTLA) — Financial statements
Income statement, balance sheet, and cash flow for Intellia Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 68↑16.9% | 58↑59.6% | 36↓30.4% | 52↑57.7% | 33 | |
| Cost of Revenue | 16↑54.8% | 10↑14.6% | 9↑18.5% | 8↑9.9% | 7 | |
| Gross Profit | 52↑8.7% | 48↑74.3% | 27↓38.7% | 45↑70.3% | 26 | |
| Operating Expenses | ||||||
| R&D Expenses | 389↓16.6% | 466↑7.2% | 435↑3.6% | 420↑82.8% | 230 | |
| General & Administrative Expenses | 120↓4.8% | 126↑8.0% | 116↑29.0% | 90↑27.0% | 71 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 120↓4.8% | 126↑8.0% | 116↑29.0% | 90↑27.0% | 71 | |
| Other Expenses | -16↓54.8% | -10↓14.6% | -9↓18.5% | -8↓9.9% | -7 | |
| Operating Expenses | 493↓15.3% | 582↑7.2% | 543↑7.9% | 503↑71.0% | 294 | |
| Total Costs & Expenses | 509↓14.1% | 592↑7.4% | 552↑8.1% | 510↑69.6% | 301 | |
| Operating Results | ||||||
| Operating Income | -441↑17.5% | -534↓3.7% | -515↓12.5% | -458↓71.1% | -268 | |
| Depreciation & Amortization | 16↑54.8% | 10↑14.6% | 9↑18.5% | 8↑9.9% | 7 | |
| EBITDA | -397↑24.3% | -524↓3.5% | -506↓12.4% | -451↓72.7% | -261 | |
| EBIT | -413↑22.8% | -534↓3.7% | -515↓12.5% | -458↓71.1% | -268 | |
| Interest & Other Income | ||||||
| Net Interest Income | 29↓38.9% | 48↓4.1% | 50↑483.4% | 9↑565.8% | 1 | |
| Interest Income | 29↓38.9% | 48↓4.1% | 50↑483.4% | 9↑565.8% | 1 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -28 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 28↑85.6% | 15↓55.3% | 34↑312.8% | -16↓38047.6% | -0.04 | |
| Income Before Tax | -413↑20.5% | -519↓7.9% | -481↓1.5% | -474↓77.0% | -268 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -413↑20.5% | -519↓7.9% | -481↓1.5% | -474↓77.0% | -268 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -413↑20.5% | -519↓7.9% | -481↓1.5% | -474↓77.0% | -268 | |
| Bottom-Line Net Income | -413↑20.5% | -519↓7.9% | -481↓1.5% | -474↓77.0% | -268 | |
| EPS (Basic) | -3.81↑27.4% | -5.25↑3.1% | -5.42↑12.0% | -6.16↓63.0% | -3.78 | |
| EPS (Diluted) | -3.81↑27.4% | -5.25↑3.1% | -5.42↑12.0% | -6.16↓63.0% | -3.78 | |
| Weighted Average Shares | 108↑9.6% | 99↑11.4% | 89↑15.3% | 77↑8.6% | 71 | |
| Weighted Average Diluted Shares | 108↑9.6% | 99↑11.4% | 89↑15.3% | 77↑8.6% | 71 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.